Targeted Protein Degradation (TPD) is an emerging new modality of drug
discovery that offers unprecedented therapeutic benefits over traditional protein
inhibition. Most importantly, TPD unlocks the untapped pool of the proteome that to
date has been considered undruggable. Captor Therapeutics (Captor) is the fourth
global, and first European, company that develops small molecule drug candidates
based on the principles of targeted protein degradation. Captor is located in Basel,
Switzerland and Wroclaw, Poland and exploits the best opportunities of the two sites
– experience and non-dilutive European grants, and talent pool, respectively. Through
over $38 M of funding, Captor has been active in three areas of TPD: molecular
glues, bi-specific degraders and direct degraders, ObteronsTM.
